Clinical Trial Update: Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating RO7239361 in ambulatory boys with Duchenne muscular dystrophy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• RO7239361

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Duchenne Muscular Dystrophy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-12-21